Revenue
2015
2016
2017
2018
2019
2025
Outlook Therapeutics, Inc. (OTLK)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | — | — | — | — | — | $8.1M | $3.1M | $3.8M | $3.0M | $5.2M |
| Gross profit | $57,205 | — | — | — | — | — | — | — | — | — | — |
| Research & development | $27.2M | $41.8M | $26.5M | $42.3M | $39.0M | $26.3M | $23.8M | $18.5M | $23.8M | $32.8M | $38.9M |
| Operating expenses | — | — | — | — | $51.7M | $36.8M | $44.4M | $32.7M | $39.7M | $54.3M | $51.8M |
| Operating income | −$67.1M | −$71.7M | −$53.1M | −$63.1M | −$51.7M | −$36.8M | −$36.3M | −$29.6M | −$35.9M | −$51.3M | −$46.6M |
| EBITDAderived | −$66.9M | −$71.6M | −$53.1M | −$62.9M | −$51.5M | −$36.6M | −$32.9M | −$26.6M | −$33.2M | −$49.0M | −$44.7M |
| Net income | −$62.4M | −$75.4M | −$59.0M | −$66.1M | −$53.2M | −$35.2M | −$34.5M | −$30.1M | −$38.8M | −$53.3M | −$47.4M |
| Basic EPSper diluted share | -$1.79 | -$4.06 | -$4.72 | -$0.31 | -$0.35 | -$0.67 | -$1.98 | -$1.22 | -$1.67 | -$3.67 | -$5.43 |
| Diluted EPSper diluted share | -$1.79 | -$4.06 | -$4.72 | -$0.31 | -$0.35 | -$0.67 | -$1.98 | -$1.22 | -$1.80 | -$3.67 | -$5.43 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 2, 2026Form 4 | Haddadin Yezan MuntherDirector | BuyCommon Stock | 29.0K | $0.83 | $24.1K | 66.2K |
| May 28, 2026Form 4 | GMS Ventures & Investments +1Director,TenPercentOwner | BuyCommon Stock · indirect | 8.54M | $0.59 | $5.04M | 22.09M |
| May 28, 2026Form 4 | GMS Ventures & Investments +1Director,TenPercentOwner | BuyWarrants (right to buy) · derivative · indirect | 8.57M | — | — | 8.57M |
| May 28, 2026Form 4 | GMS Ventures & Investments +1Director,TenPercentOwner | BuyWarrants (right to buy) · derivative · indirect | 3.46M | — | — | 3.46M |
| May 28, 2026Form 4 | GMS Ventures & Investments +1Director,TenPercentOwner | BuyWarrants (right to buy) · derivative · indirect | 3.46M | — | — | 3.46M |